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Although guidelines advocate the use of gadolinium enhanced imaging in the follow-up of RRMS patients, the benefit of the use of gadolinium enhancement in the subgroup treated with natalizumab could be questionable. Methods and materials: After IRB approval 201 brain scans and 24 spine exams were reviewed in consensus by 3 readers in a series of 27 patients treated with natalizumab (PS, EC, PwdG). These 27 patients were followed during a time span of 6 to 84 months (mean 49 months). Evolution of lesion load and contrast enhancement were scored. Particular interest was given to the diagnosis of PML. The results were compared with the clinical status and the treatment as reported in the patient charts. Results: Clinical evaluation resulted in 12 episodes of clinical relapse in patients treated with natalizumab, 5 patients demonstrated respectively 1, 2 or 3 relapses.
None of the MR scans in the asymptomatic patients nor in the symptomatic patient group demonstrated contrast enhancement. No sign of PML were detected. Conclusion: The benefit of T1 MR sequences post contrast as put forward in many guidelines could be questionable in the subgroup of RRMS patients treated with natalizumab. Introduction: MS is the most common autoimmune, demyelinating CNS disease in young adults. Demyelination foci lead to multiform clinical manifestations, which vary in progression, severity and associated symptoms. It presents low prevalence in the state of Mato Grosso (4.41 / 100,000 inhabitants), which is compatible with what is observed in South America, being more common in the female gender and in the white race. Objective: To describe the clinical profile of individuals with MS in Hospital Geral Universitário (HGU) of Cuibá-MT, Brazil. Methods: This is a descriptive study about the clinical profile of 15 patients identified with MS that were monitored in the Neurology Clinic of HGU, from January to April 2015. The following surveys were applied: EDSS for disability, SF-36 for quality of life, Beck Anxiety Questionnaire, and Hamilton Questionnaire for Depression. Results: The sample consists of 15 patients with a mean age of 29.8 years (12 to 59 years), F:M ratio of 0.25: 1, average time of 3.23 years since diagnostic (2 months to 12 years), average treatment time of 3.1 years (1 month to 12 years) and 80% clinically classified as relapsing-remitting. In relation to EDSS, there was a disability average of 3,26 (0-8) and, referring to QoL, SF-36 showed a mean of 54,9 (16-100) . Conclusion: The sample demonstrates a clinical profile that is similar to other regions of Brazil and the world. A small degree of disability was shown, but with significant impairment in QoL, despite the considerably short disease duration. The aim of this study was to clarify the role of clinical, laboratory and radiological factors of progression of MS in children observed during 2009-2014. Materials and methods: We have analyzed the course of MS in 40 children aged 9 to 18 years. All children were divided into two groups compared by number of patients (n = 20), sex and age. Children on the first group had EDSS b3.0 points. The second group had EDSS ≥ 3.0 points. We examined peripheral blood (PB) and cerebrospinal fluid (CSF) of all 40 children in the onset of the disease by PCR for EBV, HV 6, CMV. We analyzed the annual relapse rate (ARR) in both groups. During the first 2 years of the onset of MS we observed appearance of new T1, T2 lesions, gadolinium-enhanced (GD+) lesions on MRI brain (1.5Tesla). Results: Patients of the first group had a slower rate of progression of ARR (0.05 ± 0.25) and in PB we detected EBV in 25%, HV6 -10%, CMV -10% cases, the CSF: EBV 5%, HV6 -5%, CMV -10%. The increase of T2 and T1-lesionswas observed in 5 children, the appearance of Gd + in 2 patients. ARR of the second group was 1.5 ± 0.5. We detected EBV in PB in 60% patients, HV6-50%,CMV -45% cases, the CSF: EBV 45%, HV6-45%, CMV -60%. New T2 and T1 lesions on MRI were observed in 7 patients (35%) and appearance of Gd + lesions in 4 people (20%). 
